DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastroenteropancreatic Neuroendocrine Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Gastroenteropancreatic Neuroendocrine Tumors drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Gastroenteropancreatic Neuroendocrine Tumors treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Gastroenteropancreatic Neuroendocrine Tumors: An Overview
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. These cells release hormones that control various functions of the digestive system. The symptoms of GEP-NETs depend on where the tumor is growing in the gut and whether it produces excess hormones. By the time of diagnosis, the tumors have spread to other organs such as the liver.
GEP-NETs are debilitating as they often produce excess hormones that may cause severe symptoms. They are life-threatening if they spread to other organs in the body.
The World Health Organization (WHO) 2010 and 2017 classification system categorizes GEP-NETs into three grades based on histological differentiation and cell proliferation index, which guides treatment decisions. Tumor grade is determined by the highest number of either Ki-67 protein or mitotic count, and it offers an important prognostic value for GEP-NETs. In 2017, the WHO updated the staging classifications for pancreatic NETs (pNETs) to recognize well-differentiated grade 3 tumors, allowing for more precisely targeted treatment options for Grade III tumors.
Poorly differentiated grade 3 pNETs may continue to be treated with standard systemic chemotherapy, whereas well- and moderately differentiated grade 3 pNETs have been shown to benefit from targeted therapies (everolimus or sunitinib). Well-differentiated pNETs may even benefit from surgery.
Gastroenteropancreatic Neuroendocrine Tumors Market Key Facts
-
Gastroenteropancreatic Neuroendocrine Tumors Market size in the seven major markets was USD 2,821.2 million in 2020, which is expected to grow by 2032.
-
The incident population of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM countries was estimated to be 23,115 cases in 2020.
-
As per Masui et al. (2020), the age-adjusted overall incidence of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan was 3.53 per 100,000. Most NENs in the esophagus or lungs were neuroendocrine carcinomas (NECs), while the majority of those in the duodenum, ileum appendix, and rectum were grade 1 neuroendocrine tumors (NETs).
-
According to Dasari et al. (2017), the incidence rate of GEP-NETs in the United States was 3.56 cases per 100,000. Incidence rates of small intestinal, rectal, and pancreatic NETs were 1.05 cases per 100,000, 1.04 cases per 100,000, and 0.48 cases per 100,000, respectively.
-
As per Genus et al. (2019), among the 15,222 cases of NET diagnosed between 2013 and 2015, 50.7% were diagnosed with GEP-NENs; this patient cohort included both NETs and NECs, with the latter comprising 37% of all patients.
Gastroenteropancreatic Neuroendocrine Tumors Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Gastroenteropancreatic Neuroendocrine Tumors pipeline therapies. It also thoroughly assesses the Gastroenteropancreatic Neuroendocrine Tumors market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Gastroenteropancreatic Neuroendocrine Tumors drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Gastroenteropancreatic Neuroendocrine Tumors epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Gastroenteropancreatic Neuroendocrine Tumors epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Gastroenteropancreatic Neuroendocrine Tumors Epidemiology, Segmented as –
-
Incidence cases of Gastroenteropancreatic Neuroendocrine Tumors
-
Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors
-
Site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors
-
Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors
-
Symptoms-specific cases of Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumors market or expected to be launched during the study period. The analysis covers the Gastroenteropancreatic Neuroendocrine Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Gastroenteropancreatic Neuroendocrine Tumors drugs based on their sale and market share.
The report also covers the Gastroenteropancreatic Neuroendocrine Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Gastroenteropancreatic Neuroendocrine Tumors companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Gastroenteropancreatic Neuroendocrine Tumors Market Will Evolve and Grow by 2032 @
Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Analysis
Surgery is the primary treatment option; curative surgery should be considered even in the case of metastatic disease, when possible. For more progressed diseases, debulking and palliative surgery may reduce symptom load as well as facilitate and improve the outcomes from subsequent treatments. If present, hormonal symptoms usually be ameliorated with somatostatin analogs (SSA); a second-line option is interferon-alpha (IFN-alpha). Other treatments for NET include molecular targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT). For liver metastases, surgical resection, hepatic artery embolization (HAE), selective internal radiation therapy (SIRT), and radiofrequency ablation (RFA) or microwave ablation (MWA) can be performed
Gastroenteropancreatic Neuroendocrine Tumors Companies Actively Working in the Therapeutics Market Include
-
Novartis
-
Ipsen Biopharmaceuticals
-
Pfizer
-
ITM Isotopen Technologien Muenchen
-
Camurus AB
-
Hutchison Medipharma Limited
-
Bristol-Myers Squibb
-
Eisai Limite
-
Experior S.L.
-
Tarveda Therapeutics
-
Roche Pharma A
-
Exelixis
-
Merck Sharp & Dohme Corp
-
Recordati Inc
-
Eli Lilly and Company
-
Genentech, Inc.
-
Aveo Oncology Pharmaceuticals
-
Radiomedix
-
Orano Med
-
PharmaMar
-
Bayer
-
Trio Medicines
And Many Others
Emerging and Marketed Gastroenteropancreatic Neuroendocrine Tumors Therapies Covered in the Report Include:
-
177Lu-edotreotide (ITM’s therapeutic radiopharmaceutical)
-
CAM2029 (Camurus AB)
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis
4. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance
5. Gastroenteropancreatic Neuroendocrine Tumors Disease Background and Overview
6. Gastroenteropancreatic Neuroendocrine Tumors Patient Journey
7. Gastroenteropancreatic Neuroendocrine Tumors Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Gastroenteropancreatic Neuroendocrine Tumors Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs
10. Key Endpoints of Gastroenteropancreatic Neuroendocrine Tumors Treatment
11. Gastroenteropancreatic Neuroendocrine Tumors Marketed Therapies
12. Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs and Latest Therapeutic Advances
13. Gastroenteropancreatic Neuroendocrine Tumors Seven Major Market Analysis
14. Attribute Analysis
15. Gastroenteropancreatic Neuroendocrine Tumors Market Outlook (In US, EU5, and Japan)
16. Gastroenteropancreatic Neuroendocrine Tumors Companies Active in the Market
17. Gastroenteropancreatic Neuroendocrine Tumors Access and Reimbursement Overview
18. KOL Views on the Gastroenteropancreatic Neuroendocrine Tumors Market
19. Gastroenteropancreatic Neuroendocrine Tumors Market Drivers
20. Gastroenteropancreatic Neuroendocrine Tumors Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Postoperative Nausea and Vomiting (PONV) Market
“Postoperative Nausea and Vomiting (PONV) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Postoperative Nausea and Vomiting market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Postoperative Nausea and Vomiting market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/